# Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

> **NCT00316940** · PHASE1 · COMPLETED · sponsor: **Oncotherapeutics** · enrollment: 36 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** bortezomib
- **RADIATION:** samarium Sm 153 lexidronam pentasodium

## Key facts

- **NCT ID:** NCT00316940
- **Lead sponsor:** Oncotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-06
- **Final completion:** 2011-02
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2013-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00316940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00316940, "Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00316940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*